ALX 111: ALX1-11, parathyroid hormone (1-84) - NPS Allelix, PREOS, PTH, recombinant human parathyroid hormone, rhPTH (1-84)

What Was Tested

The paper reports a study of Parathyroid Hormone (PTH 1-84), published as a randomized controlled trial.

ALX 111 [parathyroid hormone (1-84) - NPS Allelix, recombinant human parathyroid hormone, rhPTH (1-84), PREOS] is a full-length, recombinant human parathyroid hormone.

It has potential as an anti-osteoporotic agent, due to its properties as a bone formation stimulant.

Who Took Part

The abstract describes 2600 women taking part.

PubMed indexes the participants as middle-aged adults, women only.

How the Study Was Run

The design is described as randomized, open-label, placebo-controlled and multicenter.

Because people in this Parathyroid Hormone (PTH 1-84) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Nothing was hidden in this open-label Parathyroid Hormone (PTH 1-84) study: the women and staff both knew the treatment.

A placebo (an inactive look-alike) gave the Parathyroid Hormone (PTH 1-84) group a baseline to be compared against.

More than one site took part, so the women came from several places.

What Was Measured

The subject headings attached to it are Bone Density, Clinical Trials, Phase II as Topic, Drug Industry, Osteoporosis, Postmenopausal, Parathyroid Hormone, Randomized Controlled Trials as Topic and Recombinant Proteins.

What This Means in Plain Language

The paper is a randomized, open-label and placebo-controlled study of Parathyroid Hormone (PTH 1-84) in 2600 women.

With several hundred people or more, it is a fairly large study for this kind of research.

The publication is from 2003 (Drugs in R&D), a journal based in New Zealand.

More context: the Parathyroid Hormone (PTH 1-84) compound page, all human trials.